NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis
Open Access
- 1 March 2019
- journal article
- review article
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 23 (3), 293-305
- https://doi.org/10.5588/ijtld.18.0324
Abstract
BACKGROUND: Tuberculosis (TB) patients receiving anti-tuberculosis treatment may experience serious adverse drug reactions (ADRs) such as hepatotoxicity. Variants of the N-acetyltransferase 2 (NAT2) gene may increase the risk of experiencing such toxicity events. OBJECTIVE: To provide a comprehensive evaluation of the evidence base for associations between NAT2 variants and anti-tuberculosis drug-related toxicity. METHOD: This was a systematic review and meta-analysis. We searched for studies in Medline, PubMed, EMBASE, BIOSIS and Web of Science. We included data from 41 articles (39 distinct cohorts of patients). We pooled effect estimates for each genotype on each outcome using meta-analyses stratified by country. RESULTS: We assessed the quality of the included studies, which was variable, with many areas of concern. Slow/intermediate NAT2 acetylators were statistically significantly more likely to experience hepatotoxicity than rapid acetylators (OR 1.59, 95%CI 1.26–2.01). Heterogeneity was not detected in the overall pooled analysis (I 2 = 0%). NAT2 acetylator status was significantly associated with the likelihood of experiencing anti-tuberculosis drug-related hepatotoxicity. CONCLUSION: We encountered several challenges in performing robust syntheses of data from pharmacogenetic studies, and we outline recommendations for the future reporting of pharmacogenetic studies to enable high-quality systematic reviews and meta-analyses to be performed.This publication has 73 references indexed in Scilit:
- NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapyEuropean Journal of Clinical Pharmacology, 2012
- Pharmacogenetic Study of Drug-Metabolising Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-AnalysisPLOS ONE, 2012
- Role of pharmacogenomics in the treatment of tuberculosis: a reviewPharmacogenomics and Personalized Medicine, 2012
- Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-AnalysisPLOS ONE, 2012
- Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected PatientsPLOS ONE, 2011
- Methodological quality of pharmacogenetic studies: Issues of concernStatistics in Medicine, 2008
- Worldwide distribution of NAT2 diversity: Implications for NAT2 evolutionary historyBMC Genomic Data, 2008
- Criteria of drug-induced liver disorders: Report of an International Consensus MeetingJournal of Hepatology, 1990
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986